1)日本婦人科腫瘍学会:子宮体がん治療ガイドライン2013年版.pp91-93,金原出版,2013
2)Koh WJ, Abu-Rustum NR, Bean S, et al:Uterine Neoplasms, Version 1.2018, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw 16:170-199
3)片渕秀隆:婦人科腫瘍委員会報告2015年度患者年報.日産婦誌69:1188-1201, 2017
4)Eisenhauer EA, Therasse P, Bogaerts J, et al:New response evaluation criteria in solid tumours:revised RECIST guideline(version 1.1). Eur J Cancer 45:228-247, 2009
5)Hackett NJ, De Oliveira GS, Jain UK, et al:ASA class is a reliable independent predictor of medical complications and mortality following surgery. Int J Surg 18:184-190, 2015
6)入田和男,川島康男,巌 康秀,他:日本麻酔科学会安全委員会偶発症例調査専門部会報告.麻酔53:320-335, 2004
7)American Society of Anesthesiologists. ASA Physical Status Classification System. 2014(https://www.asahq.org/resources/clinical-information/asa-physical-status-classification-system)
8)横山 隆,楠本真也,山本弥寿子,他:子宮体癌根治的放射線治療後の予後因子と再発リスク分類―Mayo criteria変法の有用性の評価―.現産婦64:47-51, 2015
9)日本放射線腫瘍学会:放射線治療計画ガイドライン2016年版.pp259-263,金原出版,2016
10)van der Steen-Banasik E, Christiaens M, Shash E, et al:Systemic review:Radiation therapy alone in medical non-operable endometrial carcinoma. Eur J Cancer 65:172-181, 2016
11)Schwarz JK, Beriwal S, Esthappan J, et al:Consensus statement for brachytherapy for the treatment of medically inoperableendometrial cancer. Brachytherapy 14:587-599, 2015
12)Inciura A, Atkocius V, Juozaityte E:Long-term results of high-dose-rate brachytherapy and external-beam radiotherapy in the primary treatment of endometrial cancer. J Radiat Res 51:675-681, 2010